Capillary Biomedical (CapBio), headquartered in Irvine, California, is focused on innovative technologies to simplify diabetes management. The company is currently developing a novel infusion set for use with insulin pumps. The company’s patented catheter improves the predictability of insulin dosing and enables patients to reliably use one catheter for seven or more days. More consistent and reliable insulin absorption will enable people with diabetes to achieve improved blood glucose control. This improved catheter doesn’t kink when inserted and works reliably day-to-day. It has multiple holes to distribute insulin to a larger volume of subcutaneous tissue than traditional infusion sets. Reliable access to more capillary blood and lymph vessels results in more consistent absorption with a more predictable effect on blood glucose levels. CapBio has assembled a veteran team of diabetes technology entrepreneurs, conducted extensive preclinical research, developed a minimal viable product, and filed multiple patent applications. The company recently completed a series seed preferred equity financing which will be used for clinical trials and regulatory clearance leading to commercial launch in 2019. Learn more by visiting www.capillarybio.com.